Short sleepers cruise by on four to six hours a night and don’t seem to suffer ill effects. Turns out they’re genetically ...

An emerging class of orexin-based drugs are on the cusp of disrupting care for sleep disorders — and potentially much more.

Additional 12-month-old homozygous Tg-SwDI mice and 5xFAD mice (Jax # 034848) were added to compare the types and distribution patterns of Aβ deposits and the numbers of orexin and MCH neurons in ...

For 2025, Alkermes plans to generate over $200 million in EBITDA while advancing its orexin program, particularly ALKS 2680, which is enrolling Phase 2 studies for narcolepsy. These studies are ...

For most of us, getting less than seven hours of sleep translates into grogginess, sluggish thinking, and an overwhelming ...

This manuscript by Tesmer and colleagues uses fiber photometry recordings, sophisticated analysis of movement, and deep learning algorithms to provide compelling evidence that activity in hypothalamic ...

Problems with sleep likely develop before motor symptoms in people with amyotrophic lateral sclerosis, a new study shows.

Previously, a vicious circle was described for depression and sleep disorders (the dysregulation of hypocretin/orexin) (1–3). Hypocretin peptides (hypocretin-1 and hypocretin-2) are excitatory ...

Idorsia has become the first drugmaker in the EU to claim approval for a drug for chronic insomnia in the dual orexin receptor antagonist class, ahead of rival drugs from Merck & Co and Eisai.